Natural innate and adaptive immunity to cancer - PubMed (original) (raw)
Review
Natural innate and adaptive immunity to cancer
Matthew D Vesely et al. Annu Rev Immunol. 2011.
Abstract
The immune system can identify and destroy nascent tumor cells in a process termed cancer immunosurveillance, which functions as an important defense against cancer. Recently, data obtained from numerous investigations in mouse models of cancer and in humans with cancer offer compelling evidence that particular innate and adaptive immune cell types, effector molecules, and pathways can sometimes collectively function as extrinsic tumor-suppressor mechanisms. However, the immune system can also promote tumor progression. Together, the dual host-protective and tumor-promoting actions of immunity are referred to as cancer immunoediting. In this review, we discuss the current experimental and human clinical data supporting a cancer immunoediting process that provide the fundamental basis for further study of immunity to cancer and for the rational design of immunotherapies against cancer.
Similar articles
- Immune surveillance of tumors.
Swann JB, Smyth MJ. Swann JB, et al. J Clin Invest. 2007 May;117(5):1137-46. doi: 10.1172/JCI31405. J Clin Invest. 2007. PMID: 17476343 Free PMC article. Review. - TGF-beta: a master switch in tumor immunity.
Gigante M, Gesualdo L, Ranieri E. Gigante M, et al. Curr Pharm Des. 2012;18(27):4126-34. doi: 10.2174/138161212802430378. Curr Pharm Des. 2012. PMID: 22630082 Review. - The interplay between innate and adaptive immunity in cancer shapes the productivity of cancer immunosurveillance.
Chang RB, Beatty GL. Chang RB, et al. J Leukoc Biol. 2020 Jul;108(1):363-376. doi: 10.1002/JLB.3MIR0320-475R. Epub 2020 Apr 9. J Leukoc Biol. 2020. PMID: 32272502 Free PMC article. Review. - The three Es of cancer immunoediting.
Dunn GP, Old LJ, Schreiber RD. Dunn GP, et al. Annu Rev Immunol. 2004;22:329-60. doi: 10.1146/annurev.immunol.22.012703.104803. Annu Rev Immunol. 2004. PMID: 15032581 Review. - Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy.
Vesely MD, Schreiber RD. Vesely MD, et al. Ann N Y Acad Sci. 2013 May;1284(1):1-5. doi: 10.1111/nyas.12105. Ann N Y Acad Sci. 2013. PMID: 23651186 Free PMC article.
Cited by
- P2 purinergic receptor expression and function in tumor-related immune cells.
Manoharan V, Adegbayi OO, Maynard JP. Manoharan V, et al. Purinergic Signal. 2024 Oct 10. doi: 10.1007/s11302-024-10054-7. Online ahead of print. Purinergic Signal. 2024. PMID: 39387963 Review. - Mechanisms of neural infiltration-mediated tumor metabolic reprogramming impacting immunotherapy efficacy in non-small cell lung cancer.
Zheng Y, Li L, Shen Z, Wang L, Niu X, Wei Y, Sun S, Zhao J. Zheng Y, et al. J Exp Clin Cancer Res. 2024 Oct 10;43(1):284. doi: 10.1186/s13046-024-03202-9. J Exp Clin Cancer Res. 2024. PMID: 39385213 Free PMC article. - Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy.
Li Q, Geng S, Luo H, Wang W, Mo YQ, Luo Q, Wang L, Song GB, Sheng JP, Xu B. Li Q, et al. Signal Transduct Target Ther. 2024 Oct 7;9(1):266. doi: 10.1038/s41392-024-01953-7. Signal Transduct Target Ther. 2024. PMID: 39370455 Free PMC article. Review. - Radiation-Induced Childhood Thyroid Cancer after the Fukushima Daiichi Nuclear Power Plant Accident.
Sokawa Y. Sokawa Y. Int J Environ Res Public Health. 2024 Sep 1;21(9):1162. doi: 10.3390/ijerph21091162. Int J Environ Res Public Health. 2024. PMID: 39338045 Free PMC article. - Advances in Immunomodulatory Mesoporous Silica Nanoparticles for Inflammatory and Cancer Therapies.
Gu B, Zhao Q, Ao Y. Gu B, et al. Biomolecules. 2024 Aug 25;14(9):1057. doi: 10.3390/biom14091057. Biomolecules. 2024. PMID: 39334825 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources